The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess the risk that patients will develop severe illness.
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Sera Prognostics, OraSure, Geneoscopy
Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.
JP Morgan Healthcare Conference, Day 3: Quanterix, Grail, GeneDx
Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of 2025.
Abbott Q4 Diagnostics Revenues up 4 Percent, Excluding COVID-19 Tests
The firm's Q4 2024 overall revenues were up 7 percent and full-year 2024 revenues were up 5 percent.
Roche Gets 510(k) Clearance, CLIA Waiver for Liat Triplex Point-of-Care STI Test
The firm will begin offering the test in the US followed by commercialization under CE marking.
Boulud also provided additional information on the company's Q4 performance, noting that it placed 900 SpotFire point-of-care PCR instruments during the quarter.
The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.